| abstract |
The present invention relates to the use of binding counterparts for 5- HT5 receptors for the treatment of neuropathological disorders, in particular, neurodegenerative and / or neurosychiatric disorders that may occur, in particular, in cerebral ischemia, stroke, epilepsy and seizures. in general, chronic schizophrenia, other psychotic disorders, dementia, in particular Alzheimer's dementia, demyelinating disorders, in particular multiple sclerosis and brain tumors. The invention also relates to processes for the identification and characterization of such union counterparts, in particular in the form of detection processes. |